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ABSTRACT
Aim: This study aimed to assess patients’ preferences for HIV treatment in an urban
Colombian population.
Methods: A Discrete Choice Experiment (DCE) was conducted. Urban Colombian HIV patients were
asked to repetitively choose between two hypothetical treatments that differ in regard to five attrib-
utes ‘effect on life expectancy’, ‘effect on physical activity’, ‘risk of moderate side effects, ‘accessibility
to clinic’ and ‘economic cost to access controls’. Twelve choice sets were made using an efficient
design. A Mixed Logit Panel Model was used for the analysis and subgroup analyses were performed
according to age, gender, education level and sexual preference.
Results: A total of 224 HIV patients were included. All attributes were significant, indicating that there
were differences between at least two levels of each attribute. Patients preferred to be able to per-
form all physical activity without difficulty, to have large positive effects on life expectancy, to travel
less than 2 h, to have lower risk of side-effects and to have subsidized travel costs. The attributes
‘effect on physical activity’ and ‘effects on life expectancy’ were deemed the most important. Sub-anal-
yses showed that higher educated patients placed more importance on the large positive effects of
HIV treatment, and a more negative preference for subsidized travel cost (5% level).
Limitations: A potential limitation is selection bias as it is difficult to make a systematic urban/rural
division of respondents. Additional, questionnaires were partly administered in the waiting rooms,
which potentially led to some noise in the data.
Conclusions: Findings suggests that short-term efficacy (i.e. effect on physical activity) and long-term
efficacy (i.e. effect on life expectancy) are the most important treatment characteristics for HIV urban
patients in Colombia. Preference data could provide relevant information for clinical and policy deci-
sion-making to optimize HIV care.
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The Human Immunodeficiency Virus (HIV) is a virus that
damages the immune system which weakens the ability to
fight everyday infections and diseases. HIV continues to be a
major global health problem. The World Health Organisation
(WHO) estimated 36.7 million people to be infected with HIV
worldwide at the end of 20161. Of this number, 1.8 million
people are estimated to live in the Latin America region2 of
which around 150,000 people in Colombia1. In 2016, the esti-
mated HIV incidence rate was at 0.12 per 1,000 inhabitants,
the prevalence rate at 0.25 per 1,000 inhabitants and AIDS-
related deaths at approximately 11,000 in Colombia2.
Colombia has a free and universal health care system,
meaning that there is free health care under the subsidized
system. Antiviral therapy is used to combat the consequen-
ces of HIV. This therapy causes a decline in fatality and mor-
bidity relating to HIV infection, and can prevent further
progression from HIV to AIDS3. However, treatment requires
lifelong intake and is characterized by a risk of development
of virus resistance when adherence is sub-optimal4. Typical
adherence rates for medications prescribed over long periods
of time are approximately 50–75%, which is considered sub-
optimal for HIV treatment5. Therefore, improving adherence
is a key determinant in successful antiretroviral therapy,
showing a strong interrelation between adherence and
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diminished rates of resistance, an increase in survival and a
higher quality of life5. Adherence to antiretroviral treatment
is, however, challenging, not only because the treatment for
HIV is lifelong but also since patients are in relative good
health and mostly without symptoms when starting therapy4.
It is, therefore, important to optimize treatment intake, and
improve adherence with HIV treatment.
Patient preferences studies are nowadays increasingly
used to inform policy decision making6. Including patient
preferences when designing and evaluating healthcare pro-
grams, can prove beneficial, and help broaden the perspec-
tive on new or existing technologies7. Incorporating needs of
the target population is paramount to enhance adoption
and sustained use of an intervention8, such as antiviral ther-
apy adherence. To elicit patient preferences in health care,
discrete choice experiments (DCE) have been increasingly
conducted in recent years. A DCE is a stated preference
method to elicit how respondents’ trade-off between attrib-
utes9. An advantage of DCE is the ability to assess the rela-
tive importance of different treatment characteristics that
influence the patient’s choice10. This model is based on the
assumption that choice differences between levels show the
preferences of patients7.
Previous studies have already explored patient preferen-
ces for HIV treatment. For instance, Muhlbacher et al.11 con-
ducted a DCE in a German population, and suggested that
patients valued emotional quality of life the most. Terris
et al.12 also showed that patients are more likely to use new
HIV prevention technology if the effectiveness was higher.
Since the majority of DCE studies are performed in western
countries9, it would be worthwhile to investigate to what
extent results of these studies can be transferred to low and
middle income countries. We previously conducted a best-
worst scaling to elicit the most important HIV/AIDS treatment
characteristics in Colombia. This study revealed that
Colombian patients mostly valued drug efficacy, maximum
prolongation of life and long duration of efficacy13.
To further investigate how people make trade-offs
between treatment attributes, a DCE was conducted as a
second step. The aim of this study is, therefore, to assess
patients’ preferences for HIV treatment in an urban
Colombian population. Results of this study could form a
basis to better cater clinical and policy decision making
regarding HIV treatment to the preferences of urban
Colombian people living with HIV.
Methods
A DCE was used to elicit patients’ preferences for HIV treat-
ment of the urban population in Colombia. HIV patients
were asked to repetitively choose between two treatment
profiles, represented by several treatment attributes. By vary-
ing these levels within each attribute and for every question,
scenarios for each choice were developed; referred to as
choice sets. This study followed guidelines described by
Lancsar and Louviere9 and the ISPOR Good Research
Practices for Conjoint Analysis Task Force7.
Attributes and levels
A two-step approach was used to identify and select attrib-
utes and levels that were estimated to be the most import-
ant treatment characteristics of HIV patients in Colombia.
First, to examine which attributes were used in previous
DCEs on patients’ preferences in HIV treatment, a literature
review was conducted in PubMed11–17. This was aided by a
previous best-worst scaling study18, which identified the
most important treatment characteristics of HIV patients in
Colombia. Based on the review and previous study, two inde-
pendent researchers (A. G. and E. S.) blindly consulted which
five attributes were preferred for inclusion. Additionally, a
senior expert (M. H.) and a Colombian HIV clinician (R. C.)
were consulted until consensus was reached. Following, each
attribute was assigned with three associated levels, based on
existing literature and the expertise of a Colombian HIV clin-
ician (R. C.). Then four researchers (A. G., E. S., M. H. and R.
C.) discussed the attribute levels until consensus was
reached, which was externally validated by a Colombian pro-
fessor of Rosario (J. G.).
Second, to further gather information about important
treatment barriers and side effects as deemed by the HIV
patients, and to validate the five attributes and their levels, a
focus group with six HIV patients of Assistencia Cientifica de
Alta Complejidad (ACAC), a HIV clinic in Bogota Colombia
was conducted on April 2018. The focus group confirmed
that patients were concerned by treatment outcomes, side-
effects and costs. As outcomes, the effect of treatment on
their life expectancy and on their daily physical activity were
deemed relevant to the patients, confirming the first two
attributes (effect on life expectancy, effect on physical activ-
ity). In addition, the risk of side-effects and the accessibility
to the clinic were relevant consideration for the patients. The
last attribute was, however, changed after the focus group,
i.e. the initially chosen attribute on frequency of visits was
replaced by a new attribute on economic costs. Patients
reported to be concerned by the economic costs of their
treatment, while the frequency of visits was not deemed
important attribute for them. Based on the two-step
approach, a final list of five attributes were included in our
DCE: effect on life expectancy, effect on physical activity, risk
of moderate side effects, accessibility to clinic and economic
costs to access controls (e.g. travel costs). Table 1 details the
complete list of the five attributes and their associated levels,
which were presented as they are in the survey.
Questionnaire
The DCE questionnaire was first drafted in English by E. S.
and A. G. After review/approval by two additional experts
(M. H. and R. C.), the questionnaire was translated to
Spanish. A pilot with 8 HIV patients was then conducted to
check understandability, and assess the applicability and
practicality of the questionnaire, in semi-structured inter-
views. Based on their comments and recommendations,
minor clarifications were added to wording.
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The choice sets were developed using the software
Ngene19. An efficient design (fractional factorial) was used to
identify the choice sets, assuming that respondents have
preferences certain accompanying levels over others (e.g.
those patients prefer a large positive effect on life expect-
ancy, and low levels of side effects). These expectations were
based on intuitive assumptions and existing studies11–17.
The final questionnaire started with an informed consent,
followed by an explanation of the assignment, as well as an
example of the choice sets (Figure 1). Block design was
applied through constructing two versions of the question-
naire, both with 12 different choice sets. Choice sets had no
option to opt-out, since opting for no treatment is not a
rational option19. The final part of the questionnaire assessed
the respondent regards the perceived difficulty of the survey
difficulty on a 7-point Likert scale, as well as eleven ques-
tions regarding age, socioeconomic status and patients views
on treatment. The questionnaires were composed in a paper
version as well as an online version. The online version was
made using Qualtrics20.
Data collection and patient recruitment
The questionnaires were administered at a HIV clinic
“Asistencia Cientifica de Alta Complejidad”, located in the
city Bogota. Data were collected in May 2018 through self-
administered questionnaires. Researchers AG and ES
approached people in the waiting room of the clinic, and
included all patients with HIV (without restrictions) if they (1)
filled in the informed consent, (2) passed the dominance
question, (3) filled in eight or more choice set questions, and
(4) were considered urban (see description of urban
patients below).
The filtering of the urban population was based two
items: “Where do you live; city and barrio?” and “How much
time does it take you to get to your clinic?” The city of
Bogota consists of twenty municipalities (“Localidades”),
which are in turn made up of more than a thousand neigh-
borhoods (“Barrios”). Respondents were classified urban if
they lived in one the “Localidades” deemed urban. For
respondents from the “Localidades” San Cristobal, Bosa and
Suba, the Barrio determined the urban/rural classification. If
the Barrio was unknown for these specific “Localidades”, any
travel time less than 2 h was classified as urban. In case the
“Localidad” was unknown altogether, the classification was
made on basis of time spent to get to the clinic, with 2 h
being the cut-off point. Any travel time under 2 h in combin-
ation with a missing value for question five was categorized
as urban (see Supplementary material for the map of
“Localidades” Bogota and the urban classification).
Data analysis
Data analysis was performed with Nlogit software
(Econometric Software, Inc, Plainview, NY) to estimate the
strength of the preferences for attributes and levels, the
trade-offs between attributes and how preferences varied by
individual respondent characteristics. The analysis of the data
was based on random utility theory7. The data were assessed
with a mixed multinomial logit model (also called random
parameter model)7. This analysis allows for preferences for
treatment to vary across our population. A standard devi-
ation (SD) parameter is estimated, revealing the heterogen-
eity between patients.
All attributes except “risk of moderate side effects” were
categorical variables. Effect coding describes the different
levels by only using ones, zeros and minus ones. Effects cod-
ing was chosen over dummy coding of categorical variables
as with dummy coding the parameter estimate for the base-
line (omitted) category cannot be recovered. Effects coding
has desirable properties in modeling conjoint-analysis data
and is widely used in many conjoint-analysis applications7.
When interpreting the analysis, the sign of the coefficients
indicates whether the level has a positive or negative effect
compared to the mean of the attribute. The magnitude of
the coefficients indicates the size of this effect. The param-
eter for the omitted category is the negative sum of the
included-category parameters and the 95% CI of the omitted
category was also based on the standard deviation and
covariance of the other levels7. One of the choice sets was
Table 1. List of attributes and levels.
Attributes Levels
Effect on life expectancy Large positive effects: Live many years more
Moderate positive effects:
Live a few more years
Mild positive effects:
Live a short while more
(a few months, less than two years)
Effect on physical activity All physical activities without difficulty
Some physical activities with difficulty
All physical activities with difficulty
Risk of moderate side effects 1%: Low risk of side effects
2.5%: Medium risk of side effects
5%: Higher risk of side effects
Accessibility to clinic Less than 2 h
Between 2 and 5 h




Low travel costs, paid by the patient
High travel costs, paid by the patient
Queson 1 
Treatment A Treatment B 
Effect on life expectancy 
Moderate posive 
effect 
Mild posive effect 
Effect on physical acvity  
All physical acvies 
without difficulty 
All physical acvies 
with difficulty 
Risk of moderate side effects 
5%: Higher risk of side 
effects 
2.5%: Medium risk of 
side effects 
Accessibility to clinic More than 5 hours Less than 2 hours 
Economic costs to access controls High travel costs Subsidized travel costs 
Which of the two treatments best 
represent your preferences? 
(Tick one box only)
Treatment A Treatment B
Figure 1. An example of a choice task in English.
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the dominance question, where one treatment is assumed to
have better utility levels for all attributes (i.e. higher positive
effect on life expectancy and physical activity, lower risk on
side effects, better accessibility and lower economic costs to
access the clinic) to test whether the respondents correctly
understood the questionnaire. If respondents failed the test
they were excluded for the analysis21.
All parameters were drawn from a normal distribution
and the estimation was conducted using 1,000 Halton draws.
The relative importance of the attributes was then estimated
with the magnitude of the coefficients using the range of
the magnitude coefficients per attribute. This conditional
relative importance of the attributes was estimated using the
coefficients’ magnitude via the range of the magnitude coef-
ficients per attribute. Preferences estimate from the model
was then used to estimate the conditional relative import-
ance of attributes; overall and per country. The range of attri-
bute-specific levels is calculated via the range approach by
measuring the difference between the highest and lowest
coefficient for the levels of the respective attribute. By divid-
ing the attribute-specific level range by the sum of all attri-
bute level ranges, the conditional relative importance is
calculated, via this method, the relative attribute importance
always depends on the range of levels chosen per attribute
and on the other attributes included in the experiment.
The MIXL model identifies for which attributes there is a
significant preference variation. However, it does not provide
insight into why this variation exists. Therefore, additional
subgroup analyses were conducted to examine if the prefer-
ences differ among subgroups in specific covariates (i.e. age,
gender, education and sexual preference). Age was classified
according to patients with an age of 38 or younger and
patients older than 38, with 38 being the average age of the
study population. Gender was reflected by male and female,
excluding the category “other”. Education was classified
according to low educated (i.e. primary and secondary
school) and high educated (i.e. engineer and university
degree). Sexual preference was classified according to het-
erosexual and homosexual, with the category bisexual and
other being excluded due to the limited number of partici-
pants reflecting these categories. Analyses were based on
interaction terms within the final model to investigate differ-
ences per attribute between each subgroup pair. A joint
model using dummy variables was, therefore, used to esti-
mate significant differences in treatment preferences
between subgroups. The data analyzed during the current




Table 2 details the respondent characteristics. The question-
naire was completed by 257 respondents of which 33 were
excluded after failing the dominance test. Eight respondents
were additionally excluded based on missing values for
“urban/rural”. The final dataset included 216 respondents.
Forty-one (19%) respondents completed the questionnaire
online, while 175 (81%) completed paper versions. Eight-nine
(41%) participants rated the perceived difficulty less than
four on a seven-point scale. An analysis including patients
who failed the dominance test provided highly simi-
lar results.
Patients’ preferences
Table 3 shows the patient preferences for all attributes. All
attributes were significant and thus important for patients.
All attributes were significant, indicating the importance for
patients, as there were significant differences between at
least two levels for each attribute (i.e. the 95% CI did not
overlap). Patients preferred to be able to perform all physical
activity without difficulty, to have large positive effects on
life expectancy, to travel less than 2 h, to have lower risk of
side-effects and subsidized travel costs. The standard devi-
ation parameters, suggesting preference variation among
patients per level, were significant for all parameters. Effect
on physical activity was deemed the most important (25%)
while economic cost of control was the least important (15%).
Subgroup analysis
No significant differences were found between subgroups
according to age, gender and sexual preference. Significant
differences were however observed between education sub-
groups. Table 4 details the coefficients and standard
Table 2. Patient characteristics.


























Missing values 9 4.17
Perceived difficulty task






7 (high) 10 0.05
Missing values 36 16.67
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deviation for both low educated and high educated respond-
ents. The results showed significant differences for the effect
on life expectancy and the economic cost to access controls.
First, the higher the educated group significantly value, the
more the large positive effects of HIV treatment (p< .10).
Second, higher educated patients significantly valued less
subsidized travel cost than low educated patients (p< .05).
Discussion
This study is the first to elicit patient preferences for HIV
treatment of the urban population of Colombia, and provide
insights into the weightings of the attribute levels. It also
provides insights into the differences in trade-off between
subgroups. It is important to understand the preferences of
Table 3. Results from Mixed Multinomial Logit model.
Attributes and levels Coefficient 95% CI SD 95% CI Relative importance
Effect on life expectancy 23.0%
Large positive effects 0.62 (0.47,0.76) 0.52 (0.39,0.65)
Moderate positive effects 0.11 (0.20,0.02) 0.23 (0.05,0.40)
Mild positive effects(Ref) 0.50 (0.65,0.37)
Effect of physical activity 25.0%
All physical activities without difficulty 0.63 (0.50,0.75) 0.44 (0.31,0.58)
Some physical activities with difficulty 0.04 (0.12,0.05) 0.02 (0.74,0.77)
All physical activities with difficulty (Ref) 0.59 (0.73,0.45)
Risk of moderate side effects 17.3%
1% increase in risk of side effects 0.21 (0.27,0.15) 0.13 (0.04,0.22)
Accessibility to clinic 20.5%
Less than 2 h 0.46 (0.35,0.57) 0.41 (0.28,0.54)
Between 2 and 5 h 0.08 (0.01,0.17) 0.24 (0.08,0.40)
More than 5 h (Ref) 0.54 (0.69,0.41)
Economic costs to access controls 14.2%
Subsidized travel costs 0.24 (0.13,0.36) 0.37 (0.23,0.51)
Low travel costs, paid by the patient 0.22 (0.12,0.32) 0.35 (0.20,0.49)
High travel costs, paid by the patient (Ref) 0.47 (0.61,0.33)
Pseudo R-squared ¼ 0.11; log likelihood ¼ 1,566. SD values correspond to the random component of the model coefficients.
Abbreviations. CI, confidence interval; SD, standard deviation.p< .01, p< .05, p< .1.
Table 4. Subgroup analysis on education: low education versus high education.





Effect on life expectancy
Large positive effects 0.50 (0.32–0.68) 0.78 (0.54–1.02) .07
SD: 0.43 SD: 0.64
Moderate positive effects 0.04 (0.21 to 0.04) 0.14 (0.28 to 0.01) .54
SD: 0.17 SD: 0.31
Mild positive effects (Ref) 0.46 0.64
Effect of physical activity
All physical activities without difficulty 0.54 (0.37–0.71) 0.78 (0.56–0.99) .19
SD: 0.42 SD: 0.53
Some physical activities with difficulty 0.06 (0.18 to 0.05) 0.00 (0.13 to 0.13) .47
SD: 0.11 SD: 0.05
All physical activities with difficulty (Ref) 0.48 0.78
Risk of moderate side effects
1% increase in risk of side effects 0.20 (0.28 to 0.12) 0.24 (0.35 to 0.14) .52
SD: 0.10 SD: 0.05
Accessibility to clinic
Less than 2 h 0.47 (0.32–0.63) 0.44 (0.26–0.62) .56
SD: 0.38 SD: 0.49
Between 2 and 5 h 0.09 (0.02 to 0.21) 0.04 (0.11 to 0.18) .47
SD: 0.13 SD: 0.32
More than 5 h (Ref) 0.56 0.47
Economic costs to access controls
Subsidized travel costs 0.35 (0.18–0.52) 0.12 (0.05 to 0.28) .04
SD: 0.48 SD: 0.13
Low travel costs, paid by the patient 0.17 (0.02–0.31) 0.31 (0.16–0.46) .14
SD: 0.41 SD: 0.23
High travel costs, paid by the patient (Ref) 0.52 0.43
Number of observations 112 (low educated) and 100 (high educated); Pseudo R-squared ¼ 0.10 (low educated) and 0.14 (high educated);
log likelihood ¼ 820 (low educated) and 695.86 (high educated). SD values correspond to the random component of the model
coefficients.
Abbreiations. CI, confidence interval; SD, standard deviation.p< .01, p< .05, p< .1.
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specific populations as needs may vary across groups.
Even the disproportionately affected by HIV, may be less
likely to take antiretroviral therapies22. Understanding the
patients’ preferences for HIV treatment could contribute to
better health communication to enhance uptake of treat-
ment. HIV patients valued a treatment with effect on physical
activities without difficulty, with large positive effects on life
expectancy, with less than 2 h of travel time and being subsi-
dized travel costs. The effect on physical activity was deemed
the most important attribute followed by the effect on life
expectancy and the risk of moderate side effects. The per-
formed subgroup analyses showed no significant differences
for age, gender and sexual preference. However, patients
with a higher education had a relatively higher preference
for the large positive effects of HIV treatment, and a stronger
dispreference for subsidized travel cost.
These results are mostly in line with prior studies11–17.
Muhlbacher et al.11 also suggested that patients valued the
attribute “emotional quality of life” the most. In the previ-
ously conducted best-worst scaling in Colombia13, patients
mostly valued drug efficacy, maximum prolongation of life
and long duration of efficacy.
Moreover, a similar DCE study conducted in the rural
population of Bogota, showed similar results. Both, urban
and rural, populations deemed the attributes “effect on phys-
ical activity” and “effects on life expectancy” as most import-
ant. For rural as well as urban patients, compared to patients
categorized as low educated, patients categorized as high
educated preferred large effects regards life expectancy and
deemed travel costs as less important. The results of our
study are therefore in line with other literature, which hints
at transferability to a Colombian population. However, more
research is needed to understand why physical activity was
found to be relatively important to the higher educated sub-
group in the rural population, while this difference was not
found in the urban population.
Understanding patients’ preferences for HIV treatment
may inform future consensus or design meetings regards
HIV treatment policy, designing medication adherence edu-
cation or creating patient centered HIV treatment. Results
may therefore contribute to the development of future poli-
cies taking into account the preferences of HIV patients
(e.g. “all physical activity without difficulty”, “large positive
effects on life expectancy” and less than 2 h travel time”).
Incorporating patient needs may enhance adherence to
therapy (i.e. antiretroviral treatment). Policy interventions
are needed to address serious problems in public transport
(e.g. with large congestions) due to the lack of under-
ground mass transport, which is reflected by the value
patients attach to a reduced travel time to access special-
ized points of care. In turn, enhancing adherence by incor-
porating patient needs may lead to societal impact.
Literature shows adherence to antiretroviral therapy, pro-
longs and improves the lives of HIV patients23,24, which
positively affects health outcomes, care efficiency, and prod-
uctivity, which may reduce societal costs. Patients’ preferen-
ces are nowadays increasingly investigated and used as
they can provide relevant insights for policy and clinical
decision making. Our study showed that HIV treatments
benefits (i.e. effect on physical activity and the effect on life
expectancy), risks but also costs and the access to the clin-
ics are important for patients. Incorporating the needs
regards these attributes may enhance treatment adherence,
which in turn improves the lives of HIV patients23,24.
This study has several limitations. One potential limita-
tion is the risk of selection bias. The questionnaire only
reached urban patients that visited one HIV clinic. Bogota
officially has more than nine million inhabitants25, and a
large part of these are displaced citizens from rural parts. It
is challenging to make a systematic urban/rural division of
respondents at the HIV clinic. For example, many displaced
people live in Bogota but still have a traditional rural way
of living. This increases the likelihood of rural respondents
being included in the urban study population. Another limi-
tation is that the attribute levels may be considered
ambiguous, such as “large” and “moderate” which may
reflect different meanings for different individuals.
Attributes were also presented as they are without provid-
ing a detailed description per attribute, which means that
attributes may be interpreted differently across participants.
Moreover, significant differences were identified in the sub-
group analyses, reflecting real differences between groups.
Yet, due to a small sample size, the lack of differences
between other subgroup pairs could be due to a lack of
power. Furthermore, some bias in the data collection may
have occurred as the questionnaire was partly administered
in the waiting room, which may include distractions such
as noise and time of appointment.
In conclusion, the present study revealed that all included
attributes were important for HIV treatment. The effect on
physical activity and the effect on life expectancy were the
most valued attributes. This information could help decision
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